LENZ Therapeutics, Inc.
LENZNasdaq
$5.18
↑ +6.1%Jul 17 close · end-of-day
Price
1Y↓ -85.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$162.4M
Enterprise Value
$137.6M
P/E
—
P/S
7.7
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
-53.8%
Dividend Yield
—
Revenue (TTM)
$21.0M
Net Income (TTM)
-$109.0M
Free Cash Flow (TTM)
-$87.4M
Gross Margin
—
Operating Margin
-563.8%
Net Margin
-519.3%
ROE
-44.2%
ROIC
-42.2%
Debt / Equity
—
Net Cash
$24.8M
Return 1Y
-85.0%
Company profile
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
- CEO
- Evert B. Schimmelpennink
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Headquarters
- California
- Website
- lenz-tx.com
Management & directors
- Chevallard Daniel R.Chief Financial Officer
- Schimmelpennink Evert B.President, CEO and Secretary
- Olsson ShawnChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
LENZ Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.9M—
Diluted EPS-$1.32↑ +149.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $19.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$13.5M | -$60.4M | -$105.6M | -$72.4M | -$58.6M | -$91.1M |
| Net income | -$68.4M | -$70.8M | -$101.1M | -$70.0M | -$49.8M | -$82.1M |
| Diluted EPS | — | -$2.45 | -$1.84 | -$35.71 | -$2.34 | -$2.85 |
| Operating cash flow | -$8.7M | -$52.9M | -$88.0M | -$60.4M | -$59.4M | -$69.2M |
| Free cash flow | -$10.3M | -$58.6M | -$94.6M | -$60.4M | -$59.9M | -$70.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -477.5% |
| Net margin | — | — | — | — | — | -430.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $0.00 | $5.0M | $12.5M | $1.6M | $1.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$14.4M | -$12.9M | -$15.2M | -$16.9M | -$16.9M | -$18.9M | -$38.5M | -$44.1M |
| Net income | -$10.3M | -$10.2M | -$12.7M | -$14.6M | -$14.9M | -$16.7M | -$35.9M | -$41.5M |
| Diluted EPS | -$0.40 | -$0.38 | $1.97 | -$0.53 | -$0.53 | -$0.59 | -$1.20 | -$1.32 |
| Operating cash flow | -$15.8M | -$10.6M | -$9.1M | -$16.0M | -$11.5M | -$8.6M | -$33.0M | -$33.6M |
| Free cash flow | -$15.9M | -$10.8M | -$9.2M | -$16.2M | -$11.7M | -$9.0M | -$33.1M | -$33.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -337.1% | -151.1% | -2422.1% | -2321.7% |
| Net margin | — | — | — | — | -298.2% | -133.6% | -2260.5% | -2182.4% |
Company news
Jun 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-27 | Schimmelpennink Evert B.· President, CEO and Secretary | Buy | 28,089 | $8.95 | $251,410.59 | filing |
| 2026-03-27 | Chevallard Daniel R.· Chief Financial Officer | Buy | 7,500 | $8.57 | $64,275.00 | filing |
| 2026-03-27 | George Jeffrey P. | Buy | 5,592 | $8.92 | $49,890.15 | filing |
| 2025-11-17 | Olsson Shawn· Chief Commercial Officer | Sale | 5,788 | $26.37 | $152,611.62 | filing |
| 2025-11-17 | Olsson Shawn· Chief Commercial Officer | Sale | 4,212 | $25.74 | $108,410.56 | filing |
| 2025-11-17 | Olsson Shawn· Chief Commercial Officer | Option exercise | 10,000 | $2.08 | $20,800.00 | filing |
| 2025-11-07 | MCCOLLUM JAMES W | Buy | 10,500 | $22.79 | $239,278.20 | filing |
| 2025-11-07 | Chevallard Daniel R.· Chief Financial Officer | Buy | 2,178 | $22.76 | $49,562.79 | filing |
| 2025-11-07 | Chevallard Daniel R.· Chief Financial Officer | Buy | 20 | $22.71 | $454.20 | filing |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Sale | 83,066 | $46.41 | $3.9M | filing |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Sale | 57,502 | $46.41 | $2.7M | filing |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Sale | 49,701 | $45.35 | $2.3M | filing |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Sale | 34,405 | $45.35 | $1.6M | filing |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Sale | 177 | $47.01 | $8,321.35 | filing |
| 2025-09-30 | Versant Venture Capital VI, L.P. | Sale | 123 | $47.01 | $5,782.64 | filing |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Sale | 49,479 | $41.59 | $2.1M | filing |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Sale | 40,907 | $43.00 | $1.8M | filing |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Sale | 24,370 | $41.59 | $1.0M | filing |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Sale | 20,148 | $43.00 | $866,440.56 | filing |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Sale | 268 | $43.30 | $11,604.40 | filing |
| 2025-09-18 | Versant Venture Capital VI, L.P. | Sale | 132 | $43.30 | $5,715.60 | filing |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Sale | 43,978 | $38.97 | $1.7M | filing |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Sale | 21,661 | $38.97 | $844,224.48 | filing |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Sale | 3,465 | $39.50 | $136,875.12 | filing |
| 2025-08-26 | Versant Venture Capital VI, L.P. | Sale | 1,707 | $39.50 | $67,430.26 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.